Aprea Therapeutics Business Summary

Aprea Therapeutics, Inc. (APRE) is a clinical-stage biopharmaceutical company that operates through a research-intensive business model, primarily generating revenue via government grants, strategic R&D collaborations, and the potential future commercialization or licensing of its DNA damage response (DDR) platform. The company’s primary business segments are dedicated to the development of small-molecule therapeutics that target synthetic lethality in genetically defined cancers. Its core pipeline features APR-1051, a next-generation WEE1 inhibitor, and ATRN-119, a macrocyclic ATR inhibitor, both of which are currently undergoing Phase 1 clinical evaluation for advanced solid tumors. In the competitive landscape of DDR-targeted oncology, Aprea competes with major players such as BeiGene, Jazz Pharmaceuticals, and Zentalis Pharmaceuticals, positioning itself as a developer of differentiated, "next-generation" inhibitors designed to offer superior safety profiles and oral bioavailability over first-generation predecessors. Originally founded on research from Sweden’s Karolinska Institute, the current leadership team is spearheaded by President and CEO Oren Gilad, Ph.D., who previously founded and led Atrin Pharmaceuticals until its 2022 acquisition by Aprea. Key executives include SVP and CFO John P. Hamill, who brings over 30 years of financial expertise from Windtree Therapeutics, and Senior Medical Advisor Philippe Pultar, M.D., a specialist in WEE1 clinical development formerly with Zentalis. The company’s strategic oversight is provided by a distinguished board, including Chairman Richard Peters, M.D., Ph.D. (formerly CEO of Yumanity Therapeutics), and Jean-Pierre Bizzari, M.D., a former Celgene executive who oversaw the approval of numerous blockbuster oncology therapies. Aprea is backed by notable institutional investors such as Janus Henderson Investors, Versant Ventures, and 5AM Ventures.